Endocrinology in the News: Semaglutide for Weight Loss

Last week Novo Nordisk published the results of their trial of semaglutide (marketed as Ozempic for type 2 diabetes) for weight loss in overweight and obese patients without diabetes.  I have been waiting for these results for a long time.  Today I will share why. Semaglutide is part of a class of medications called GLP-1Continue reading “Endocrinology in the News: Semaglutide for Weight Loss”